Generic Name and Formulations:
Sumatriptan (as succinate) 6mg/0.5mL; soln for SC inj.
Indications for ALSUMA:
Acute treatment of migraine or cluster headaches.
Limitations Of use:
Confirm diagnosis; reconsider if no response after treatment. Not for prevention of migraine attacks.
≥18yrs: one (6mg) dose SC to the lateral thigh or upper arm only. Reevaluate if no response. May repeat after 1hr; max two (6mg) doses in 24hrs. Avoid IM or IV administration.
<18yrs: not recommended.
Ischemic coronary artery disease (CAD) (eg, angina, history of MI, silent ischemia). Coronary artery vasospasm (including Prinzmetal's angina). Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders. History of stroke or TIA. History or evidence of hemiplegic or basilar migraine. Peripheral vascular disease. Ischemic bowel disease. Uncontrolled hypertension. Within 24hrs of ergot-type drugs (eg, methysergide, dihydroergotamine) or other 5-HT1 agonists. During or within 2 weeks of an MAO-A inhibitor. Severe hepatic impairment.
Exclude underlying cardiovascular disease, supervise 1st dose, and consider monitoring ECG in patients with multiple cardiovascular risk factors (eg, increased age, diabetes, hypertension, smokers, obesity, strong family history of CAD). Monitor BP, cardiovascular function in long-term intermittent use. Discontinue if serious arrhythmias or cerebrovascular events occur. Peripheral vascular or colonic ischemia following other 5-HT1 agonists. Discontinue if serotonin syndrome is suspected. History, or risk of seizures. Elderly. Pregnancy (Cat.C). Nursing mothers: avoid for 12hrs after dose.
Selective 5-HT1B/1D receptor agonist.
Ergotamines, other 5-HT1 agonists, MAO-A inhibitors: see Contraindications. Increased risk of serotonin syndrome with SSRIs, SNRIs, tricyclics, or MAO inhibitors.
Inj site reactions, tingling, dizziness/vertigo, warm/hot or burning sensation, feeling of heaviness or tightness, pressure sensation, flushing, numbness, tight feeling in head, chest or jaw/nasal cavity/sinuses discomfort, drowsiness/sedation, headache; rare: serious cardiac and cerebrovascular events (including fatalities), hypertension, vision loss, hypersensitivity reactions.
Single-use auto-injector (prefilled)—2/pack
Endocrinology Advisor Articles
- Testosterone Use Remains High Among Men With Coronary Artery Disease
- Primary Characteristics of PCOS Predictive of Obstetric Complications
- Comparing Osteoporosis Screening, Treatment Strategies in Postmenopausal Women
- Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
- Cerebral Small Vessel Disease More Common in Individuals With T1D vs General Population
- ADA's 2019 Standards of Medical Care in Diabetes Focus on Patient-Centered Care
- Sleep Habits Affect Insulin Sensitivity in Adolescents With Overweight, Obesity
- Levothyroxine Associated With Increased Mortality in Patients With Heart Failure
- Head-to-Head Comparison of Professional vs Personal CGM Systems in T1D
- Dual vs Triple Therapy for Metformin Treatment Intensification in Type 2 Diabetes
- Insulin Analogs vs Regular Human Insulin for Type 2 Diabetes
- Diabetic Ketoacidosis May Affect Brain Development in Children With T1D
- Higher Rates of Comorbidities Among Holocaust Survivors
- Population Health Data May Help Identify Patients at Risk for CVD
- Newborn Genomic Sequencing Can Identify Disease Risk